{
  "abstract": "Purpose\n\nTo evaluate very early anatomical and functional outcomes following a switch from intravitreal bevacizumab to aflibercept-jbvf in patients with exudative macular diseases.Methods\n\nThis prospective, single-center, single-arm interventional cohort study included 53 eyes of 41 patients with diabetic macular edema (DME), macular neovascularization (MNV) secondary to neovascular age-related macular degeneration, or retinal vein occlusion (RVO). This heterogeneous cohort comprised biologically distinct disease entities; therefore, diagnosis-specific analyses were considered exploratory. All eyes received three monthly intravitreal bevacizumab injections followed by a single aflibercept-jbvf injection. Primary outcomes were changes in BCVA and CST from the post-bevacizumab preswitch baseline, assessed immediately before aflibercept-jbvf administration, to 4 weeks after the injection. The Wilcoxon signed-rank test was used for paired comparisons, and generalized estimating equation models accounted for within-patient intereye correlation in bilateral cases.Results\n\nAmong 53 eyes, 30 (56.6%) had DME, 18 (34.0%) had MNV, and five (9.4%) had RVO. Median CST decreased from 312 μm (IQR, 275-354 μm) at preswitch baseline to 291 μm (IQR, 255-322 μm) at week 4. The mean CST change was - 22.6 ± 68.1 μm (95% CI, - 40.9 to - 4.2; p = 0.001). Median BCVA was 0.699 logMAR at both the post-bevacizumab preswitch baseline (IQR, 0.495-1.000) and week 4 (IQR, 0.398-1.000). The mean BCVA change was - 0.051 ± 0.230 logMAR (95% CI, - 0.114 to + 0.013; p = 0.129). In the GEE analyses, CST reduction remained statistically significant (p = 0.005), whereas BCVA change was not significant after adjustment for within-patient intereye correlation (β = -0.051; p = 0.065). No serious adverse events were observed.Conclusion\n\nAdministration of aflibercept-jbvf following three monthly bevacizumab injections was temporally associated with a statistically significant but modest very early reduction in CST at 4 weeks in this heterogeneous cohort of exudative macular diseases. Because DME, neovascular AMD-related MNV, and RVO represent biologically and clinically distinct disease entities, the pooled findings should be interpreted as descriptive cohort-level estimates within this shared treatment pathway rather than as evidence of a uniform treatment effect across these conditions. A small numerical trend toward BCVA improvement was observed, but the change was not statistically significant in either the unadjusted or GEE-adjusted analysis. Because this was a single-arm study without a comparator group, the observed anatomical change cannot be attributed specifically to aflibercept-jbvf and may partly reflect a delayed or cumulative response to prior bevacizumab, regression to the mean, or natural variability in retinal thickness. Diagnosis-specific findings were exploratory, and the 4-week endpoint does not provide information regarding durability of response or longer-term treatment burden.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Ophthalmology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, 03030, Türkiye. tugcehorozoglu00@gmail.com.",
    "Department of Ophthalmology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, 03030, Türkiye."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Tugce Horozoglu Ceran",
      "orcid": "0000-0003-2132-3098"
    },
    {
      "affs": [
        1
      ],
      "name": "Selma Beyatli",
      "orcid": "0009-0000-1309-1704"
    },
    {
      "affs": [
        1
      ],
      "name": "Mustafa Dogan",
      "orcid": "0000-0001-7237-9847"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8hmrnz7e3sqtv.bib",
  "cited_by": 0,
  "doi": "10.1186/s12886-026-05491-4",
  "fulltext_url": "https://europepmc.org/articles/PMC13721706",
  "id": "8hmrnz7e3sqtv",
  "issns": [
    "1471-2415"
  ],
  "landing_url": "https://europepmc.org/article/MED/42958502",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research"
    ],
    [
      "openalex",
      "2731|Retinal Diseases and Treatments"
    ]
  ],
  "openalex": "W7224110362",
  "pdf_url": "https://europepmc.org/articles/PMC13721706?pdf=render",
  "pmcid": "PMC13721706",
  "pmid": "42958502",
  "published": "2026-10-28",
  "publisher": "BMC",
  "ris": "https://research.draconitic.com/paper/8hmrnz7e3sqtv.ris",
  "sources": [
    {
      "first_seen": "2026-11-01T00:20:36Z",
      "native_id": "MED:42958502",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42958502"
    },
    {
      "first_seen": "2026-11-03T12:22:21Z",
      "native_id": "PMC13721706",
      "source": "pmc",
      "url": "https://doi.org/10.1186/s12886-026-05491-4"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2731|Retinal Diseases and Treatments",
      "subfield": "general"
    }
  ],
  "title": "Early outcomes of switching from bevacizumab to aflibercept-jbvf in exudative macular diseases: a real-world study.",
  "title_text": "Early outcomes of switching from bevacizumab to aflibercept-jbvf in exudative macular diseases: a real-world study.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T12:22:21Z",
  "url": "https://research.draconitic.com/paper/8hmrnz7e3sqtv",
  "venue": "BMC ophthalmology",
  "versions": []
}